BRIEF-Humacyte Atev Met Superiority Primary Endpoint Compared To Standard Of Care Av Fistula In Interim Analysis Of V012 Phase 3 Study In Female Dialysis Access Patients

Humacyte, Inc.

Humacyte, Inc.

HUMA

0.00

June 10 (Reuters) - Humacyte Inc HUMA.O:

  • HUMACYTE ATEV MET SUPERIORITY PRIMARY ENDPOINT COMPARED TO STANDARD OF CARE AV FISTULA IN INTERIM ANALYSIS OF V012 PHASE 3 STUDY IN FEMALE DIALYSIS ACCESS PATIENTS

  • HUMACYTE - TO FILE SUPPLEMENTAL BLA WITH FDA IN SECOND HALF OF 2026

  • HUMACYTE - STUDY ENROLLMENT TO TERMINATE AFTER MEETING PRIMARY ENDPOINT

Source text: ID:nGNX8ZbM72

Further company coverage: HUMA.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.